Thyroid-stimulating hormone in hypothyroidism – How high is too high?

R. Senthiappan, Smitha S. Bhat, S. Krishna
{"title":"Thyroid-stimulating hormone in hypothyroidism – How high is too high?","authors":"R. Senthiappan, Smitha S. Bhat, S. Krishna","doi":"10.4103/ami.ami_76_18","DOIUrl":null,"url":null,"abstract":"Background: The prevalence of hypothyroidism in the developed world is about 4-5% and in India is 10.9%. The goal of treating hypothyroidism is to maintain thyrotropin (TSH) levels within the normal reference range. Studies have shown that even within the normal range of TSH, patients with low normal TSH (LNT) have better outcomes when compared to patients with high normal TSH (HNT). Aims and Objectives: Our study aimed to find whether patients treated at a dose of levothyroxine resulting in an LNT had improved clinical outcomes and biochemical parameters, when compared to those on a levothyroxine dose resulting in an HNT. Materials and Methods: 180 patients with hypothyroidism on treatment, who had a TSH of 0.27-4.2mIU/L and had been on treatment with a stable dose of at least 50 micrograms of levothyroxine for at least 6 months were administered the Thyroid Symptom Questionnaire. TSH was assayed. Blood pressure and BMI were measured. Serum lipids were measured by spectrophotometry. Results: We found that patients with LNT and HNT did not differ with respect to cognitive symptoms , feelings of coldness, lethargy and fatigue. However, patients with LNT had a better lipid profile (mean LDL 132.24 in HNT and 115.39 in LNT p= 0.08) and lower BMI (1.045kg/m 2 lower in LNT compared to HNT) compared to HNT. Conclusion: Treating patients with a dose of thyroxine titrated to achieve LNT might decrease the cardiovascular risk by improving the lipid profile and BMI.","PeriodicalId":32506,"journal":{"name":"Acta Medica International","volume":"26 1","pages":"11 - 16"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/ami.ami_76_18","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The prevalence of hypothyroidism in the developed world is about 4-5% and in India is 10.9%. The goal of treating hypothyroidism is to maintain thyrotropin (TSH) levels within the normal reference range. Studies have shown that even within the normal range of TSH, patients with low normal TSH (LNT) have better outcomes when compared to patients with high normal TSH (HNT). Aims and Objectives: Our study aimed to find whether patients treated at a dose of levothyroxine resulting in an LNT had improved clinical outcomes and biochemical parameters, when compared to those on a levothyroxine dose resulting in an HNT. Materials and Methods: 180 patients with hypothyroidism on treatment, who had a TSH of 0.27-4.2mIU/L and had been on treatment with a stable dose of at least 50 micrograms of levothyroxine for at least 6 months were administered the Thyroid Symptom Questionnaire. TSH was assayed. Blood pressure and BMI were measured. Serum lipids were measured by spectrophotometry. Results: We found that patients with LNT and HNT did not differ with respect to cognitive symptoms , feelings of coldness, lethargy and fatigue. However, patients with LNT had a better lipid profile (mean LDL 132.24 in HNT and 115.39 in LNT p= 0.08) and lower BMI (1.045kg/m 2 lower in LNT compared to HNT) compared to HNT. Conclusion: Treating patients with a dose of thyroxine titrated to achieve LNT might decrease the cardiovascular risk by improving the lipid profile and BMI.
促甲状腺激素在甲状腺功能减退中的作用——多高才算过高?
背景:发达国家甲状腺功能减退症的患病率约为4-5%,印度为10.9%。治疗甲状腺功能减退的目标是将促甲状腺激素(TSH)水平维持在正常参考范围内。研究表明,即使在正常TSH范围内,与高正常TSH (HNT)患者相比,低正常TSH (LNT)患者的预后更好。目的和目的:我们的研究旨在发现与左旋甲状腺素导致HNT的患者相比,左旋甲状腺素导致LNT的患者是否有改善的临床结果和生化参数。材料与方法:180例正在治疗的甲状腺功能减退患者,TSH为0.27 ~ 4.2 miu /L,且左旋甲状腺素稳定剂量≥50微克治疗至少6个月,填写甲状腺症状问卷。测定TSH。测量血压和身体质量指数。用分光光度法测定血脂。结果:我们发现LNT和HNT患者在认知症状、冷感、嗜睡和疲劳方面没有差异。然而,与HNT相比,LNT患者具有更好的脂质谱(HNT患者平均LDL为132.24,LNT患者平均LDL为115.39,p= 0.08)和更低的BMI(与HNT相比,LNT患者低1.045kg/ m2)。结论:通过甲状腺素滴定治疗达到LNT可能通过改善血脂和BMI来降低心血管风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信